Clinical trial · Observational
Liver Cancer Registry Platform
JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Physician's choice according to patient's needs. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Hepatocellular Carcinoma (HCC)
- description
- Patients with Hepatocellular Carcinoma (HCC)
- interventionNames
- Other: Physician's choice according to patient's needs.
- label
- Cholangiocarcinoma (CCC)
- description
- Patients with Cholangiocarcinoma (CCC)
- interventionNames
- Other: Physician's choice according to patient's needs.
Primary outcomes (1)
- measure
- Course of treatment (treatment reality).
- timeFrame
- 3 years per patient.
- description
- Documentation of anamnestic data and therapy sequences.
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/metastatic stage * Age ≥ 18 years * Signed and dated informed consent (IC): * For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment * For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment Exclusion criteria: Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)
References
Publications (0)
Data not yet available